title: Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor.
abstract: OBJECTIVE
  To assess the efficacy of definitive treatment of sacral chordoma by high-dose proton/photon-beam radiation therapy alone or combined with surgery.
  
  
  METHODS
  The records of 16 primary and 11 recurrent sacral chordoma patients treated from November 1982 to November 2002 by proton/photon radiation therapy alone (6 patients) or combined with surgery (21 patients) have been analyzed for local control, survival, and treatment-related morbidity. The outcome analysis is based on follow-up information as of 2005.
  
  
  RESULTS
  Outcome results show a large difference in local failure rate between patients treated for primary and recurrent chordomas. Local control results by surgery and radiation were 12/14 vs. 1/7 for primary and recurrent lesions. For margin-positive patients, local control results were 10 of 11 and 0 of 5 in the primary and recurrent groups, respectively; the mean follow-up on these locally controlled patients was 8.8 years (4 at 10.3, 12.8, 17, and 21 years). Radiation alone was used in 6 patients, 4 of whom received > or =73.0 Gy (E); local control was observed in 3 of these 4 patients for 2.9, 4.9, and 7.6 years.
  
  
  CONCLUSIONS
  These data indicate a high local control rate for surgical and radiation treatment of primary (12 of 14) as distinct from recurrent (1 of 7) sacral chordomas. Three of 4 chordomas treated by > or =73.0 Gy (E) of radiation alone had local control; 1 is at 91 months. This indicates that high-dose proton/photon therapy offers an effective treatment option.
authors.affiliation: Department of Radiation, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. lilypark@hotmail.com
authors.forename: Lily
authors.initials: L
authors.lastname: Park
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Delaney
authors.forename: Norbert J
authors.initials: NJ
authors.lastname: Liebsch
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Hornicek
authors.forename: Saveli
authors.initials: S
authors.lastname: Goldberg
authors.forename: Henry
authors.initials: H
authors.lastname: Mankin
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Rosenberg
authors.forename: Daniel I
authors.initials: DI
authors.lastname: Rosenthal
authors.forename: Herman D
authors.initials: HD
authors.lastname: Suit
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D002817:Chordoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D017785:Photons / Q000627:therapeutic use; D061766:Proton Therapy; D012447:Sacrum; D016019:Survival Analysis; D016896:Treatment Outcome; D011522:Protons
chemical_list: D011522:Protons